Federal watchdog seeks public's opinion on how to protect Canadians from excessively priced patented medicines

Friday, November 22, 2019 Drug News
Email Print This Page Comment bookmark
Font : A-A+

The PMPRB is holding public consultations on its proposed new pricing Guidelines

OTTAWA, Nov. 21, 2019 /CNW/ - The Patented Medicine Prices Review Board (PMPRB) released its new draft Guidelines today and launched a 60-day consultation period with stakeholders and interested members of the public. This consultation follows Health Canada's recent amendments to the Patented Medicines Regulations, which strengthen and modernize Canada's pricing framework for patented drugs so that the PMPRB can better protect Canadian consumers from excessive prices in an era marked by increasingly high cost drugs.

The Guidelines explain the steps taken by staff at the PMPRB in assessing whether a patented drug appears to be priced excessively in Canada. It also explains what information patent-holding pharmaceutical companies must provide to the PMPRB to enable it to make that assessment.

The deadline for providing written submissions to PMPRB.Consultations.CEPMB@pmprb-cepmb.gc.ca is January 20, 2020. The PMPRB consultation plan also provides for multiple feedback opportunities and formats. Full details are available on the PMPRB's website.

Quotes"The PMPRB is committed to hearing from Canadians on how it can continue to ensure they are protected from excessively priced patented drugs and looks forward to receiving constructive and meaningful feedback on the proposed changes to its Guidelines."Dr. Mitchell LevineChairperson, PMPRB

Quick Facts

  • On August 9, 2019, Health Canada announced amendments to the Patented Medicines Regulations which will come into force on July 1, 2020.
  • Major changes to the PMPRB's Guidelines are necessary to implement the regulatory amendments.
  • The PMPRB ensures that prices charged by pharmaceutical companies for patented drugs sold in Canada are not excessive.
  • The PMPRB also reports on pharmaceutical trends and R&D spending by pharmaceutical patentees.
Associated Links

  • Draft Guidelines
  • Consultation Background – PMPRB Draft Guidelines
  • Regulations Amending the Patented Medicines Regulations, Canada Gazette
Follow us on Twitter: @PMPRB_CEPMB

SOURCE Patented Medicine Prices Review Board



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Premium Membership Benefits

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store